Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2015

Open Access 01-12-2015 | Research

Opposing roles for mammary epithelial-specific PPARγ signaling and activation during breast tumour progression

Authors: Anthony J Apostoli, Jennifer M Roche, Mark M Schneider, Sandip K SenGupta, Michael A Di Lena, Rachel E Rubino, Nichole T Peterson, Christopher JB Nicol

Published in: Molecular Cancer | Issue 1/2015

Login to get access

Abstract

Background

Among women worldwide, breast cancer is the most commonly diagnosed cancer, and the second leading cause of cancer-related deaths. Improved understanding of breast tumourigenesis may facilitate the development of more effective therapies. Peroxisome proliferator-activated receptor (PPAR)γ is a transcription factor that regulates genes involved in insulin sensitivity and adipogenesis. Previously, we showed, using 7,12-dimethylbenz [a] anthracene (DMBA)-treated haploinsufficient PPARγ mice, that PPARγ suppresses breast tumour progression; however, the PPARγ expressing cell types and mechanisms involved remain to be clarified. Here, the role of PPARγ expression and activation in mammary epithelial cells (MG) with respect to DMBA-mediated breast tumourigenesis was investigated.

Methods

PPARγ MG knockout (PPARγ-MG KO) mice and their congenic, wild-type controls (PPARγ-WT) were treated once a week for six weeks by oral gavage with 1 mg DMBA dissolved in corn oil and maintained on a normal chow diet. At week 7, mice were randomly divided into those maintained on a normal chow diet (DMBA Only; PPARγ-WT: n = 25 and PPARγ-MG KO: n = 39) or those receiving a diet supplemented with the PPARγ ligand, rosiglitazone (ROSI, 4 mg/kg/day) (DMBA + ROSI; PPARγ-WT: n = 34 and PPARγ-MG KO: n = 17) for the duration of the 25-week study.

Results

Compared to DMBA Only-treated PPARγ-WTs, both breast tumour susceptibility and serum levels of proinflammatory and chemotactic cytokines, namely IL-4, eotaxin, GM-CSF, IFN-γ, and MIP-1α, were decreased among PPARγ-MG KOs. Cotreatment with ROSI significantly reduced breast tumour progression among PPARγ-WTs, correlating with increased BRCA1 and decreased VEGF and COX-2 protein expression levels in breast tumours; whereas, surprisingly DMBA + ROSI-treated PPARγ-MG KOs showed increased breast tumourigenesis, correlating with activation of COX-2.

Conclusion

These novel data suggest MG-specific PPARγ expression and signaling is critical during breast tumourigenesis, and may serve as a strong candidate predictive biomarker for response of breast cancer patients to the use of therapeutic strategies that include PPARγ ligands.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon, France. 2013. http://​globocan.​iarc.​fr. Accessed 16/04/2015.
2.
Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137(1):354–66. doi:10.1210/endo.137.1.8536636.PubMed
3.
Jain S, Pulikuri S, Zhu Y, Qi C, Kanwar YS, Yeldandi AV, et al. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol. 1998;153(2):349–54.CrossRefPubMedCentralPubMed
4.
Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1998;1(3):465–70.CrossRefPubMed
5.
Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A. 1998;95(15):8806–11.CrossRefPubMedCentralPubMed
6.
Kotta-Loizou I, Giaginis C, Theocharis S. The role of peroxisome proliferator-activated receptor-gamma in breast cancer. Anticancer Agents Med Chem. 2012;12(9):1025–44.CrossRefPubMed
7.
8.
Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007;28(12):551–8. doi:10.1016/j.it.2007.09.003.CrossRefPubMed
9.
Bortolini M, Wright MB, Bopst M, Balas B. Examining the safety of PPAR agonists - current trends and future prospects. Expert Opin Drug Saf. 2013;12(1):65–79. doi:10.1517/14740338.2013.741585.CrossRefPubMed
10.
Kim JH, Hubbard NE, Ziboh V, Erickson KL. Conjugated linoleic acid reduction of murine mammary tumor cell growth through 5-hydroxyeicosatetraenoic acid. Biochim Biophys Acta. 2005;1687(1–3):103–9. doi:10.1016/j.bbalip.2004.11.007.PubMed
11.
Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR, et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun. 2001;286(5):916–22. doi:10.1006/bbrc.2001.5491.CrossRefPubMed
12.
Nicol CJ, Yoon M, Ward JM, Yamashita M, Fukamachi K, Peters JM, et al. PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis. 2004;25(9):1747–55. doi:10.1093/carcin/bgh160.CrossRefPubMed
13.
Skelhorne-Gross G, Reid AL, Apostoli AJ, Di Lena MA, Rubino RE, Peterson NT, et al. Stromal adipocyte PPARgamma protects against breast tumorigenesis. Carcinogenesis. 2012;33(7):1412–20. doi:10.1093/carcin/bgs173.CrossRefPubMed
14.
Apostoli AJ, Skelhorne-Gross GE, Rubino RE, Peterson NT, Di Lena MA, Schneider MM, et al. Loss of PPARgamma expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment. Int J Cancer. 2014;134(5):1055–66. doi:10.1002/ijc.28432.CrossRefPubMedCentralPubMed
15.
Cui Y, Miyoshi K, Claudio E, Siebenlist UK, Gonzalez FJ, Flaws J, et al. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem. 2002;277(20):17830–5. doi:10.1074/jbc.M200186200.CrossRefPubMed
16.
Fiennes AG. Growth rate of human tumour xenografts measured in nude mice by in vivo cast modelling. Br J Surg. 1988;75(1):23–4.CrossRefPubMed
17.
Pignatelli M, Cocca C, Santos A, Perez-Castillo A. Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line. Oncogene. 2003;22(35):5446–50. doi:10.1038/sj.onc.1206824.CrossRefPubMed
18.
Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, et al. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev. 2004;18(5):528–40. doi:10.1101/gad.1167804.CrossRefPubMedCentralPubMed
19.
Yin Y, Yuan H, Zeng X, Kopelovich L, Glazer RI. Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification. Cancer Res. 2009;69(2):687–94. doi:10.1158/0008-5472.CAN-08-2446.CrossRefPubMedCentralPubMed
20.
Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol. 2002;22(8):2607–19.CrossRefPubMedCentralPubMed
21.
Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem. 2003;278(36):34268–76. doi:10.1074/jbc.M300043200.CrossRefPubMed
22.
Nicol CJ, Adachi M, Akiyama TE, Gonzalez FJ. PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens. 2005;18(4 Pt 1):549–56. doi:10.1016/j.amjhyper.2004.10.032.CrossRefPubMed
23.
Rosak C, Standl E, Reblin T, Stammer H, Seidel DK. Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes. Int J Clin Pract. 2006;60(9):1040–7. doi:10.1111/j.1742-1241.2006.01092.x.CrossRefPubMed
24.
Dream_Trial_Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096–105. doi:10.1016/S0140-6736(06)69420-8.CrossRef
25.
Welters HJ, El Ouaamari A, Kawamori D, Meyer J, Hu J, Smith DM, et al. Rosiglitazone promotes PPARgamma-dependent and -independent alterations in gene expression in mouse islets. Endocrinology. 2012;153(10):4593–9. doi:10.1210/en.2012-1243.CrossRefPubMedCentralPubMed
26.
Takata Y, Liu J, Yin F, Collins AR, Lyon CJ, Lee CH, et al. PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci U S A. 2008;105(11):4277–82. doi:10.1073/pnas.0708647105.CrossRefPubMedCentralPubMed
27.
Ghosh S, Lu Y, Katz A, Hu Y, Li R. Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells. Am J Physiol Endocrinol Metab. 2007;292(1):E246–52. doi:10.1152/ajpendo.00242.2006.CrossRefPubMed
28.
Hoellen F, Kelling K, Dittmer C, Diedrich K, Friedrich M, Thill M. Impact of cyclooxygenase-2 in breast cancer. Anticancer Res. 2011;31(12):4359–67.PubMed
29.
Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003;97(12):2978–87. doi:10.1002/cncr.11437.CrossRefPubMed
30.
Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002;62(6):1676–81.PubMed
31.
Thill M, Fischer D, Becker S, Cordes T, Dittmer C, Diedrich K, et al. Prostaglandin metabolizing enzymes in correlation with vitamin D receptor in benign and malignant breast cell lines. Anticancer Res. 2009;29(9):3619–25.PubMed
32.
Diaz-Cruz ES, Shapiro CL, Brueggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab. 2005;90(5):2563–70. doi:10.1210/jc.2004-2029.CrossRefPubMed
33.
Hazra S, Dubinett SM. Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells. Prostaglandins Leukot Essent Fatty Acids. 2007;77(1):51–8. doi:10.1016/j.plefa.2007.05.006.CrossRefPubMedCentralPubMed
34.
Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol. 2001;11(10):764–8.CrossRefPubMed
35.
Meade EA, McIntyre TM, Zimmerman GA, Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem. 1999;274(12):8328–34.CrossRefPubMed
36.
Patel KM, Wright KL, Whittaker P, Chakravarty P, Watson ML, Ward SG. Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPAR(gamma) agonists: evidence for disparate functional effects which are independent of NF-(kappa)B and PPAR(gamma). Cell Signal. 2005;17(9):1098–110. doi:10.1016/j.cellsig.2004.12.002.CrossRefPubMed
37.
Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, Stearman R, et al. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol. 2008;73(3):709–17. doi:10.1124/mol.107.042002.CrossRefPubMed
38.
Ackerman WE, Zhang XL, Rovin BH, Kniss DA. Modulation of cytokine-induced cyclooxygenase 2 expression by PPARG ligands through NFkappaB signal disruption in human WISH and amnion cells. Biol Reprod. 2005;73(3):527–35. doi:10.1095/biolreprod.104.039032.CrossRefPubMedCentralPubMed
39.
Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, et al. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A. 2000;97(9):4844–9.CrossRefPubMedCentralPubMed
40.
Pujols L, Benitez P, Alobid I, Martinez-Anton A, Roca-Ferrer J, Mullol J, et al. Glucocorticoid therapy increases COX-2 gene expression in nasal polyps in vivo. Eur Respir J. 2009;33(3):502–8. doi:10.1183/09031936.00017408.CrossRefPubMed
41.
Matthews L, Berry A, Tersigni M, D'Acquisto F, Ianaro A, Ray D. Thiazolidinediones are partial agonists for the glucocorticoid receptor. Endocrinology. 2009;150(1):75–86. doi:10.1210/en.2008-0196.CrossRefPubMedCentralPubMed
42.
Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol. 2003;23(17):6159–73.CrossRefPubMedCentralPubMed
43.
Ahmed F, Wyckoff J, Lin EY, Wang W, Wang Y, Hennighausen L, et al. GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice. Cancer Res. 2002;62(24):7166–9.PubMed
44.
Nolen BM, Lokshin AE. Targeting CCL11 in the treatment of ovarian cancer. Expert Opin Ther Targets. 2010;14(2):157–67. doi:10.1517/14728220903512983.CrossRefPubMed
45.
Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res. 2008;79(3):360–76. doi:10.1093/cvr/cvn120.CrossRefPubMedCentralPubMed
46.
Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol. 2004;36(10):1882–6. doi:10.1016/j.biocel.2003.10.019.CrossRefPubMed
47.
Peeters LL, Vigne JL, Tee MK, Zhao D, Waite LL, Taylor RN. PPAR gamma represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis. 2005;8(4):373–9. doi:10.1007/s10456-005-9027-4.CrossRefPubMed
48.
Kawai H, Li H, Chun P, Avraham S, Avraham HK. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene. 2002;21(50):7730–9. doi:10.1038/sj.onc.1205971.CrossRefPubMed
49.
Singh-Ranger G, Salhab M, Mokbel K. The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat. 2008;109(2):189–98. doi:10.1007/s10549-007-9641-5.CrossRefPubMed
50.
51.
McKenzie AN, Culpepper JA, De Waal MR, Briere F, Punnonen J, Aversa G, et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci U S A. 1993;90(8):3735–9.CrossRefPubMedCentralPubMed
Metadata
Title
Opposing roles for mammary epithelial-specific PPARγ signaling and activation during breast tumour progression
Authors
Anthony J Apostoli
Jennifer M Roche
Mark M Schneider
Sandip K SenGupta
Michael A Di Lena
Rachel E Rubino
Nichole T Peterson
Christopher JB Nicol
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2015
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-015-0347-8

Other articles of this Issue 1/2015

Molecular Cancer 1/2015 Go to the issue

Research

The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells

Research

Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma

Research

Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells

Research

Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway

Research

Deregulation of the FOXM1 target gene network and its coregulatory partners in oesophageal adenocarcinoma

Research

Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits